A comparative study of the two leadless pacemakers in clinical practice.
effectiveness
leadless pacemaker
pacing
safety
ventricular arrhythmias
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
01
05
2023
received:
03
02
2023
accepted:
13
07
2023
medline:
18
9
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
AVEIR-VR leadless pacemaker (LP) was recently approved for clinical use. Although trial data were promising, post-approval real world data with regard to its effectiveness and safety is lacking. To report our early experience with AVEIR-VR LP with regard to its effectiveness and safety and compare it with MICRA-VR. The first 25 patients to undergo AVEIR-VR implant at our institution between June and November 2022, were compared to 25 age- and sex-matched patients who received MICRA-VR implants. In both groups, mean age was 73 years and 48% were women. LP implant was successful in 100% of patients in both groups. Single attempt deployment was achieved in 80% of AVEIR-VR and 60% of MICRA-VR recipients (p = 0.07). Fluoroscopy, implant, and procedure times were numerically longer in the AVEIR-VR group compared to MICRA-VR group (p > 0.05). No significant periprocedural complications were noted in both groups. Incidence of ventricular arrhythmias were higher in the AVEIR-VR group (20%) compared to the MICRA-VR group (0%) (p = 0.043). At 2 and 8 weeks follow-up, device parameters remained stable in both groups with no device dislodgements. The estimated battery life at 8 weeks was significantly longer in the AVEIR-VR group (15 years) compared to the MICRA-VR group (8 years) (p = 0.047). With 3-4 AVEIR-VR implants, the learning curve for successful implantation reached a steady state. Our initial experience with AVEIR-VR show that it has comparable effectiveness and safety to MICRA-VR. Larger sample studies are needed to confirm our findings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1896-1903Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009-a World Society of Arrhythmia's Project: 2009 survey cardiac pacemakers and ICDS. Pacing Clin Electrophysiol. 2011;34:1013-1027.
Udo EO, Zuithoff NPA, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:728-735.
Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014;129:1466-1471.
Ritter P, Duray GZ, Steinwender C, et al. Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. Eur Heart J. 2015;36:2510-2519.
Reddy VY, Exner DV, Cantillon DJ, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med. 2015;373:1125-1135.
Reddy VY, Exner DV, Doshi R, et al. Primary results on safety and efficacy from the LEADLESS II-phase 2 worldwide clinical trial. JACC: Clin Electrophysiol. 2022;8:115-117.
Reynolds D, Duray GZ, Omar R, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016;374:533-541.
FDA. Aveir leadless pacing system-Aveir leadless pacemaker, model LSP112V (right ventricular); Aveir delivery catheter, model LSCD111; and Aveir link module, module LSL02-P150035.
Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Europace. 2008;10:707-725.
Ritter P, Duray GZ, Zhang S, et al. The rationale and design of the Micra Transcatheter Pacing Study: safety and efficacy of a novel miniaturized pacemaker. Europace. 2015;17:807-813.
Eggen MD, Grubac V, Bonner MD. Design and evaluation of a novel fixation mechanism for a transcatheter pacemaker. IEEE Trans Biomed Eng. 2015;62:2316-2323.
El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control. Heart Rhythm. 2018;15:1800-1807.
Da Costa A, Romeyer-Bouchard C, Guichard JB, Gerbay A, Isaaz K. Is the new Micra-leadless pacemaker entirely safe? Int J Cardiol. 2016;212:97-99.
Amin AK, Billakanty SR, Chopra N, et al. Premature ventricular contraction-induced polymorphic ventricular tachycardia after leadless pacemaker implantation: a unique adverse effect of leadless pacing. HeartRhythm Case Rep. 2018;4:180-183.
Olsen FJ, Højlund S, Jacobsen MD. Malignant ventricular tachycardia and cardiac arrest induced by a micra™ leadless pacemaker. J Electrocardiol. 2018;51:1053-1054.
Lazzerini PE, Laghi-Pasini F, Bertolozzi I, et al. Systemic inflammation as a novel QT prolonging risk factor in patients with torsades de pointes. Heart. 2017;103:1821-1829.